SARS-CoV-2 T Cell Immunity

In collaboration with Charite (Prof. Andreas Thiel) the T Cell immune response to SARS-CoV-2 infection and vaccination was systematically analyzed. For the first time, this revealed the presence of SARS-CoV-2-reactive T cells not only in patients with COVID-19 but also in healthy donors (Braun et al., Nature 2020). Upon vaccination with BNT162b2, strong T cell immunity was developed with a kinetics that resembled that of secondary immune responses. Furthermore, a universal immunodominant coronavirus-specific peptide epitope (iCope) was identified (Loyal et al., medRxiv 2021).



References

References

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Braun et al., Nature 2020
Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
Loyal et al., medRxiv (2021)
Technologies
Partner

Partner

Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité–Universitätsmedizin Berlin, Berlin, Germany (Prof. Andreas Thiel)
Loading...